Our Partners

Fibrocell collaborates with industry and academic partners.

Fibrocell and Castle Creek Pharmaceuticals are working in collaboration to develop and commercialize FCX-007, our gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).  Castle Creek is a privately held biopharmaceutical company developing innovative therapies for patients with rare, serious or debilitating dermatologic conditions.  The company, with offices in Parsippany, New Jersey and Chicago, Illinois, is dedicated to developing and bringing novel therapies to those living with epidermolysis bullosa.  Castle Creek’s most advanced program, named CCP-020, is an investigational topical therapy for the treatment of epidermolysis bullosa simplex, or EBS.  CCP-020 is complementary to FCX-007, and together they represent a robust EB pipeline for treating a broader population of patients.



Fibrocell has entered into exclusive channel collaborations (ECCs) with Intrexon Corporation (NASDAQ: XON), a leader in synthetic biology, to facilitate the assembly and delivery of the necessary target gene constructs for delivery to autologous fibroblasts. Access to Intrexon’s technology platform allows Fibrocell a rapid method to screen and construct the best genetic therapeutic solutions.


Collaborating with Fibrocell

Fibrocell welcomes discussion with pharmaceutical, academic and government organizations that share the company’s vision and can bring assets that complement its development strategies. Interested parties should contact Fibrocell at 484.713.6000 or send a non-confidential email.